Please enable JavaScript
Powered by Benchmark Matribhumi Samachar English - Page 502 of 3045 -
Tuesday, March 24 2026 | 09:20:57 AM

BluMetric Announces Closing of $15 Million Brokered Offering

Ottawa, Ontario–(Newsfile Corp. – December 9, 2025) – BluMetric Environmental Inc. (TSXV: BLM) (OTCQX: BLMWF) (“BluMetric” or the “Company“), an engineering WaterTech and full-service environmental consulting firm, is pleased to announce that the Company has closed its previously announced best-efforts brokered offering of 11,538,461 common shares of the Company (the …

Read More »

Element One Completes The 2025 Exploration Program on The HY Project

Exploration on Element One’s HY Project successfully identified nickel-bearing ultramafic units that will be tested to evaluate hydrogen-stimulation and nickel-silicate extraction potential Vancouver, British Columbia–(Newsfile Corp. – December 9, 2025) – Element One Hydrogen & Critical Minerals Corp. (CSE: EONE) (“Element One” or the “Company“) is pleased to report that the Company has …

Read More »

NU E Power Corp. Announces Upcoming Appointment of Hon. Tony Clement to Board of Directors to Support Advanced Energy and SMR Strategy

Calgary, Alberta–(Newsfile Corp. – December 9, 2025) – NU E Power Corp. (CSE: NUE) (OTC Pink: NUEPF) (“Nu E” or the “Company”) is pleased to announce that the Honorable Tony Clement, former Canadian Cabinet Minister, is expected to be appointed to the Company’s Board of Directors following its upcoming Annual …

Read More »

Custom Health Announces First Closing of Brokered Private Placement of Subscription Receipts for Gross Proceeds of US$9.6M

Kelowna, British Columbia–(Newsfile Corp. – December 9, 2025) – Custom Health Inc. (“Custom Health” or the “Company“), a vertically integrated, tech-enabled care platform, is pleased to announce that Custom FundCo Inc. (“FundCo“) has completed the first closing (the “First Closing“) of its previously announced brokered private placement financing of subscription …

Read More »

Steppe Gold Provides Q4 Production Update Change of Auditor

Ulaanbaatar, Mongolia–(Newsfile Corp. – December 9, 2025) – Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold” or the “Company“) is pleased to report upgraded production guidance for the fourth quarter of 2025. Following the major fleet upgrades in 2025, ongoing maintenance work and recovery of downtime experienced …

Read More »

Canadian Metals Initiates Drill Program and Update on the Comprehensive Re-Evaluation Review Across Its New Brunswick Properties and Grants Options

Montreal, Quebec–(Newsfile Corp. – December 9, 2025) – Canadian Metals Inc. (CSE: CME) (“CME” or the “Company“) is pleased to announce the commencement of ~3,200-metre drill program targeting several high-priority areas, and provide an update on the ongoing comprehensive technical review and re-evaluation of its five 100%-owned mineral properties located …

Read More »

Kenorland Minerals Provides an Exploration Update

Vancouver, British Columbia–(Newsfile Corp. – December 9, 2025) – Kenorland Minerals Ltd. (TSXV: KLD) (OTCQX: KLDCF) (FSE: 3WQ0) (“Kenorland” or the “Company“) is pleased to provide an update on its exploration activities across its portfolio of projects in Quebec, Ontario, Manitoba, Saskatchewan, New Brunswick, and Alaska, including partnerships with Sumitomo …

Read More »

Valkea Resources Strengthens the Bulk-Tonnage Gold Potential of the Koivu Zone at the Paana Project, Northern Finland

Vancouver, British Columbia–(Newsfile Corp. – December 9, 2025) – Valkea Resources Corp. (TSXV: OZ) (OTCQB: OZBKF) (the “Company” or “Valkea“) is pleased to announce drill results from the 2025 fall exploration drill program at its 100% owned Paana project in Lapland, Finland. The 2,454-meter, seven-hole drill program targeted bulk-tonnage gold mineralization at the …

Read More »

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study design Biomarker data advanced as key pre-specified surrogate clinical efficacy endpoint, with pending analysis awaiting alignment with US FDA on biomarker statistical analysis plan to be discussed at upcoming December 11, 2025 FDA Type C Meeting …

Read More »